Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -890.82% is 384% below its 5-year average of -184.10%, around the middle of its 5-year range (-1373.78%–-79.48%).
414.15% below its 12-month average of -173.26%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2022 (2022-03-31): -172.41%.
EBITDA MARGIN
-890.82%
EBITDA MARGIN AVG TTM
-173.26%
EBITDA MARGIN AVG 3Y
-187.49%
EBITDA MARGIN AVG 5Y
-184.10%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-414.15%
CURRENT VS 3Y AVG
-375.12%
CURRENT VS 5Y AVG
-383.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aptevo Therapeutics Inc.
Market Cap
$4.03M
EBITDA Margin
-890.82%
TTM Avg
-173.26%
3Y Avg
-187.49%
5Y Avg
-184.10%
Market Cap
$4.14M
EBITDA Margin
-38402.78%
TTM Avg
-17909.83%
3Y Avg
-9620.57%
5Y Avg
-7243.11%
Market Cap
$4.13M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
Market Cap
$4.26M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$3.73M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$4.34M
EBITDA Margin
-445.85%
TTM Avg
-1797.00%
3Y Avg
-2252.67%
5Y Avg
-1514.30%
Market Cap
$4.38M
EBITDA Margin
-13851.65%
TTM Avg
-8371.58%
3Y Avg
-4777.88%
5Y Avg
-3394.57%
Market Cap
$3.54M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $4.03M | -890.82% | -173.26% | -187.49% | -184.10% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.14M | -38402.78% | -17909.83% | -9620.57% | -7243.11% |
| GRI Bio, Inc. (GRI)vs › | $4.13M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.26M | -159.06% | -237.19% | -222.87% | -159.05% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.73M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -445.85% | -1797.00% | -2252.67% | -1514.30% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.38M | -13851.65% | -8371.58% | -4777.88% | -3394.57% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.54M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Nexalin Technology, Inc. (NXL)vs › | $3.52M | -2774.55% | -3680.87% | -3159.91% | -3026.36% |
Gross Margin
0.0%
EBITDA Margin
-890.8%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-03-31 | -172.41% |
| 2021-12-31 | -103.25% |
| 2021-09-30 | -143.90% |
| 2021-06-30 | -174.37% |
| 2021-03-31 | -272.37% |
| 2020-12-31 | -277.16% |
| 2020-09-30 | -406.43% |
| 2020-06-30 | -1373.78% |
| 2019-12-31 | -79.48% |
| 2019-09-30 | -111.01% |
| 2019-06-30 | -167.43% |
| 2019-03-31 | -154.61% |
| 2018-12-31 | -204.63% |
| 2018-09-30 | -197.97% |
| 2018-06-30 | -173.51% |
| 2018-03-31 | -317.22% |
| 2017-12-31 | -592.09% |
| 2017-09-30 | -154.44% |
| 2017-06-30 | -88.17% |
| 2017-03-31 | -115.39% |
| 2016-12-31 | -335.43% |
| 2016-09-30 | -744.91% |
| 2016-06-30 | -117.37% |
| 2016-03-31 | -150.56% |
| 2015-12-31 | -213.52% |
| 2015-09-30 | -188.92% |
| 2015-06-30 | -248.12% |
| 2015-03-31 | -90.13% |
